Welcome to our dedicated page for ARCH BIOPARTNERS ORD news (Ticker: ACHFF), a resource for investors and traders seeking the latest updates and insights on ARCH BIOPARTNERS ORD stock.
Arch Biopartners Inc. (OTCQB: ACHFF) is a clinical-stage biopharmaceutical company focused on developing new therapies for the prevention of inflammation and acute organ injury. Their primary area of research targets the dipeptidase-1 (DPEP-1) pathway, which plays a crucial role in inflammation in the lungs, kidneys, and liver.
The Company's leading drug candidate, LSALT peptide, aims to treat and prevent cardiac surgery-associated acute kidney injury (CS-AKI), a significant complication following cardiac surgeries, particularly those involving cardiopulmonary bypass. LSALT peptide has received approval for Phase II trials in several countries, including Turkey and Canada. Arch Biopartners is also exploring other potential applications for LSALT peptide, such as treating inflammation caused by SARS-CoV-2 virus infection.
In their latest developments, Arch Biopartners announced several milestones, including:
- Approval from the Turkish Ministry of Health and Health Canada for Phase II trials targeting CS-AKI.
- Patient recruitment and dosing have begun in Turkey, with participation from multiple hospital sites.
- Collaboration with major research institutions like the University of Calgary's Cumming School of Medicine and the University Health Network in Toronto.
- Publication of Phase II trial results for LSALT Peptide in the British Medical Journal Open detailing its efficacy in reducing inflammation.
Arch Biopartners operates with a robust intellectual property portfolio and actively collaborates with leading researchers and institutions to advance their drug candidates. The Company has 62,755,633 common shares outstanding and provides detailed investor information and scientific publications on their website.
Arch Biopartners Inc. (TSX Venture: ARCH, OTCQB: ACHFF) announced that its drug candidate cilastatin will participate in the PONTIAC Phase II trial, targeting acute kidney injury (AKI) caused by drug toxins. The 900-patient trial, funded by $1.9 million in grants, will evaluate cilastatin's efficacy in preventing AKI from antibiotics, chemotherapeutics, and radiographic contrast. Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as an AKI treatment, leveraging its unique ability to block toxin uptake in kidney tissue. This trial complements Arch's ongoing Phase II study of LSALT peptide for cardiac surgery-associated AKI. Together, these trials target about 50% of hospital AKI cases, for which no treatment currently exists.
Arch Biopartners has announced the completion of the good manufacturing practice (GMP) glass vial filling stage for cilastatin, their second drug candidate aimed at preventing acute kidney injury (AKI). Dalton Pharma Services finalized this stage, and over the next six to eight weeks, will complete the quality control process. This will result in the release of the first-ever stand-alone cilastatin drug product, which is set to be used in a Phase II trial for drug toxin-related AKI in hospitalized patients. The trial is expected to commence in late 2024. Arch will partner with Canadian clinical researchers, providing cilastatin, scientific, and regulatory support. The company holds method of use patents in North America and Europe for repurposing cilastatin as an AKI treatment. This milestone is a significant step in their plans to introduce cilastatin as a novel treatment for toxin-related AKI.
Arch Biopartners has received ethics approval from the University of Calgary's Conjoint Health Research Ethics Board to initiate a Phase II trial for the LSALT peptide. This trial targets the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The approval allows the clinical team at the University of Calgary to finalize preparations and training for patient recruitment. This process is expected to continue until final approval from Alberta Health Services is obtained. Patient recruitment is already ongoing at five sites in Turkey since March, with Health Canada approving recent protocol enhancements. These enhancements are still pending approval from the Turkish Ministry of Health. CEO Richard Muruve expressed satisfaction with the trial's progress and anticipates that starting dosing in Calgary and later in Toronto will significantly benefit the trial.
FAQ
What is the current stock price of ARCH BIOPARTNERS ORD (ACHFF)?
What is the market cap of ARCH BIOPARTNERS ORD (ACHFF)?
What is Arch Biopartners Inc. focused on?
What is LSALT peptide?
What recent approvals has Arch Biopartners received for LSALT peptide?
Which hospitals are participating in the Phase II trials for LSALT peptide?
What are some key findings from the Phase II trial for LSALT peptide?
What is cardiac surgery-associated acute kidney injury (CS-AKI)?
How does LSALT peptide work?
Has Arch Biopartners published any scientific papers?
How many shares does Arch Biopartners have outstanding?
Where can I find more information about Arch Biopartners?
